Education
About Us
Working with TipRanks
Follow Us
Xenetic Biosciences (XBIO)
NASDAQ:XBIO
XBIO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.78 - $5.20
Previous CloseN/A
Volume4.73K
Average Volume (3M)4.89K
Market Cap
$4.81M
Enterprise Value-$177.52K
Total Cash (Recent Filing)$571.61K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 08, 2025EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.57
Shares Outstanding1,542,139
10 Day Avg. Volume5,679
30 Day Avg. Volume4,892
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.08
Price to Cash Flow (P/CF)-1.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda0.04
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe agreement with PeriNess accelerates DNase I based oncology program clinical development by leveraging PeriNess's expertise in drug development from preclinical to early-stage clinical programs.
Research CollaborationThe Scripps Research Institute CAR-T collaboration has been extended, potentially generating meaningful preclinical data.
Bears Say
Clinical TrialsPreclinical model update at SITC further builds DNase I preclinical profile; Phase 1 studies expected in 2025.
---
Ownership Overview
―
Insiders
1.38% Mutual Funds
0.89% Other Institutional Investors
97.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XBIO FAQ
What was Xenetic Biosciences’s price range in the past 12 months?
Xenetic Biosciences lowest stock price was $2.78 and its highest was $5.20 in the past 12 months.
What is Xenetic Biosciences’s market cap?
Xenetic Biosciences’s market cap is $4.81M.
When is Xenetic Biosciences’s upcoming earnings report date?
Xenetic Biosciences’s upcoming earnings report date is May 08, 2025 which is in 39 days.
How were Xenetic Biosciences’s earnings last quarter?
Xenetic Biosciences released its earnings results on Nov 13, 2024. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.14 by -$0.14.
Is Xenetic Biosciences overvalued?
According to Wall Street analysts Xenetic Biosciences’s price is currently Overvalued.
Does Xenetic Biosciences pay dividends?
Xenetic Biosciences does not currently pay dividends.
What is Xenetic Biosciences’s EPS estimate?
Xenetic Biosciences’s EPS estimate is -0.72.
How many shares outstanding does Xenetic Biosciences have?
Xenetic Biosciences has 1,542,139 shares outstanding.
What happened to Xenetic Biosciences’s price movement after its last earnings report?
Xenetic Biosciences reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.14. Following the earnings report the stock price went down -11.622%.
Which hedge fund is a major shareholder of Xenetic Biosciences?
Currently, no hedge funds are holding shares in XBIO
---
Company Description
Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
---
XBIO Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cyclacel Pharmaceuticals
―
Avadel Pharmaceuticals
―
ADMA Biologics
―
Cellectar Biosciences
―
Citius Pharmaceuticals
―
---